At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 707 enrolled
Drug / intervention
Cabozantinib tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
In Brief
A Phase 3 clinical trial evaluating Cabozantinib tablets and Placebo tablets for Hepatocellular Carcinoma. Completed, enrolled 707 participants across 104 sites in 19 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesAustralia, Belgium, Canada, France, Germany, Hong Kong, Ireland, Italy, Netherlands, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartSep 2013
Primary CompletionOct 2017
Study CompletionJan 2021
TodayJul 2026
First PostedJul 25, 2013
Enrollment StartSep 26, 2013
Primary CompletionOct 16, 2017
Study CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.9 years ago
Interventions
Cabozantinib tabletsdrug
Placebo tabletsdrug